Epacadostat

Epacadostat

Identifiers
IUPAC name N-(3-Bromo-4-fluorophenyl)-N′-hydroxy-4-{[2-(sulfamoylamino)ethyl]amino}-1,2,5-oxadiazole-3-carboximidamide
CAS Number	1204669-58-8
DrugBank	DB11717
ChemSpider	34448418
Chemical and physical data
Formula	C11H13BrFN7O4S
Molar mass	438.23 g·mol−1
3D model (JSmol)	Interactive image
SMILES c1cc(c(cc1N/C(=N\O)/c2c(non2)NCCNS(=O)(=O)N)Br)F
InChI InChI=1S/C11H13BrFN7O4S/c12-7-5-6(1-2-8(7)13)17-11(18-21)9-10(20-24-19-9)15-3-4-16-25(14,22)23/h1-2,5,16,21H,3-4H2,(H,15,20)(H,17,18)(H2,14,22,23) Key:FBKMWOJEPMPVTQ-UHFFFAOYSA-N

Epacadostat (previously INCB24360) is an investigational drug for cancer. Epacadostat is an inhibitor of indoleamine 2,3-dioxygenase-1) (IDO1).

As of 2017, the combination of epacadostat with pembrolizumab (Keytruda) was being investigated by Incyte and Merck & Co. in several cancers, as was the combination of epacadostat with nivolumab (Opdivo) by Incyte and Bristol Myers Squibb.